cytarabine has been researched along with Vascular Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kantarjian, HM | 1 |
| Coccia, PF; Dehner, LP; Kersey, JH; Kim, TH; Krivit, W; Nesbit, ME; Ramsay, NK; Woods, WG | 1 |
2 other study(ies) available for cytarabine and Vascular Diseases
| Article | Year |
|---|---|
Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cyclophosphamide; Cytarabine; Dexamethasone; Humans; Inotuzumab Ozogamicin; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy; Vascular Diseases | 2019 |
Fatal veno-occlusive disease of the liver following high dose chemotherapy, irradiation and bone marrow transplantation.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Burkitt Lymphoma; Child; Cytarabine; Drug Therapy, Combination; Female; Hepatic Veins; Humans; Leukemia, Myeloid, Acute; Liver; Liver Diseases; Male; Radiotherapy; Transplantation, Autologous; Transplantation, Homologous; Vascular Diseases | 1980 |